Hospital News
Return to Mesothelioma Overview
More on Mesothelioma
- Annual CT Screening for Lung Cancer Is Cost-Effective for High-Risk Persons, Study Finds
- Bexxar Effective as First-Line Treatment for Non-Hodgkin's Lymphoma Patients When Used With Chemotherapy
- Cancer Treatment Is First to Directly Target Tumor Blood Supply in Patients
- Combination of Abbreviated Chemotherapy with Radioactive Monoclonal Antibody Effective in Previously Untreated Non-Hodgkin's Lymphoma
- Coping With Chronic Cancer Pain
- Do Heart Disease and Cancer Have a Common Genetic Link?
- Female Smokers Face Double the Risk for Lung Cancer Compared to Male Smokers, NewYork-Presbyterian/Weill Cornell Study Finds
- Female Smokers Twice as Likely as Men To Develop Lung Cancer, Weill Cornell Study Finds
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Landmark Study Reveals Lung Cancer 10-Year Survival Dramatically Improves With Annual CT Screening and Prompt Treatment
- Lung Cancer CT Screening Is Cost-Effective, Weill Cornell Study Shows
- Lung Cancer Screening Regimen Provides Opportunity for Cure
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- New Book by NewYork Weill Cornell Radiologist Offers Hope to Those Who May Face Lung Cancer
- New Book by Weill Cornell Psychiatrist Offers Insight and Hope for "Surviving Cancer Emotionally"
- New Research To Address Pressing Question: Will Early Lung Cancer Detection Lead to Tobacco Cessation?
- NewYork-Presbyterian/Weill Cornell Creates World-Class Cancer Center
- NewYork-Presbyterian Hospital's Weill Cornell Medical Center Announces Preliminary Lung Cancer Data Involving Patients Treated With Arthritis Medication
- New York Weill Cornell Researchers Report CT Screening of Patients at Risk for Lung Cancer Saves Lives
- New York Weill Cornell To Lead Statewide Consortium in Early CT Screening for Lung Cancer
- Scientists Identify Cells Necessary for Tumor Angiogenesis
- Smokers and Former Smokers Should Be Screened for Lung Cancer, Even if They Do not Have Symptoms
- The Seventh Issue of Cancer Prevention Has Arrived!
- Tumor Size Predicts Survival in Most Common Type of Lung Cancer
- Two Novel Biologics Studied for Multiple Myeloma
- Weill Cornell Researchers Announce New Gene Therapy Strategy To Promote Hair Growth
Health Library
Clinical Services
Return to Mesothelioma Overview
More on Mesothelioma
- Bladder Cancer
- Blood Cancer
- Brain Cancer
- Center for Holistic Urology
- Center for Lymphoma and Myeloma
- Colon Cancer
- Early Lung Cancer Action Program
- Edward S. Harkness Eye Institute
- Esophageal Cancer
- Eye Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Kidney Cancer
- Leukemia and Myeloproliferative Disease Center
- Liver Cancer
- Lung Cancer
- Oncology (Cancer)
- Pancreatic and Biliary Cancer
- Pediatric Cancer
- Prostate Cancer
- Rectal Cancer
- Robert M. Ellsworth Ophthalmic Oncology Center
- Soft Tissue and Bone Cancer
- Spirit of Care Program
- Stomach Cancer
- Testicular Cancer
- Urologic Cancer
Mesothelioma
NewYork-Presbyterian Hospital recently established a Mesothelioma Center, unique in this area, to provide comprehensive diagnosis and treatment for this uncommon cancer. Mesothelioma originates in the membrane lining the abdominal cavity or the chest cavity, and is often seen in older patients who have been exposed to asbestos. Other causes, such as radiation and certain viruses, have sometimes been implicated.
Diagnostic Innovation
NewYork-Presbyterian Hospital offers patients the latest tools for the assessment of mesothelioma. This condition is diagnosed from biopsies of affected tissues (pleura or peritoneum) obtained surgically by thoracoscopy, thoracotomy, laparoscopy, or laparotomy. The tumor is imaged and staged by CAT scan or MRI and its metabolism assessed by newer methods of radioisotope or PET scanning. Using the latest "bench-to-beside" laboratory techniques, tumor tissue from a newly diagnosed mesothelioma patient is examined for its ability to grow outside the body, for patterns of gene expression, for tumor antigens potentially useful in constructing mesothelioma vaccines, and for sensitivity to selected chemotherapy drugs. These tests, many of which are not obtainable elsewhere, help to estimate the likelihood of effective curative or palliative therapy, and are often directly linked to treatment.
Therapeutic Excellence
Under the aegis of the Mesothelioma Center, more than 100 newly diagnosed patients with mesothelioma are cared for and followed each year from all over the country. (The total number of new cases in the U.S. is less than 3,000 per year). Most patients are seen or treated by a surgeon, medical oncologist, and radiotherapist during their course, as well as a highly specialized nursing staff and psychiatry liaison.
Experimental Therapies
Because mesotheliomas represent less than 1 percent of cancers and are infrequently seen in the practice of most community oncologists, finding the correct treatment can be very difficult. NewYork-Presbyterian Hospital's Mesothelioma Center offers patients access to the newest experimental treatments.
Peritoneal Mesothelioma
Over 50 patients with this rare disease have participated in our nationally recognized intensive multimodality treatment program, which involves debulking surgery, repeated intraperitoneal chemotherapy, second-look surgery, and whole abdominal radiation. This is a disease whose survival is traditionally 18 months or less from diagnosis. In our first clinical trial, the median survival has not yet been achieved (now over 68 months), and 37% of our patients are disease-free.
Pleural Mesothelioma
Our Center is among the leading US institutions that are evaluating new chemotherapy drugs, such as pemetrexed plus cisplatin, (currently the most effective, just recently FDA-approved drug combination), for advanced, inoperable mesothelioma; the combination of gemcitabine + cisplatin or oxaliplatin; and the amino acid analogue l-alanosine. For patients who are candidates for surgical treatment, we have implemented multimodal protocols for pre- and postoperative adjuvant chemotherapy in conjunction with surgical treatment and radiation therapy.
Whether the most up-to-date conventional or experimental plan of care is chosen, the goal of treatment is always the expeditious improvement of patient survival, symptoms, and quality of life.
Research
The Mesothelioma Center is very active in laboratory-based research in order to ensure that the newest concepts of cancer biology are used to design the most advanced investigative treatments.
Translational Studies
Our colleagues in Pulmonary Medicine and Pathology have accumulated genetic profiles from microdissected specimens of peritoneal mesothelioma tissue removed from our patients at surgery. These data will aid in diagnosis of difficult cases, and allow development of rational therapies. For example, they have discovered that 15% of mesothelioma patients who show a sarcomatoid pattern of growth and with an extremely poor prognosis (average survival 6 months or less) have a unique genetic profile that distinguishes them from the other 85% of patients; these patients also demonstrate unique biochemical features that can be used as targets for experimental drugs.
PreClinical Studies
Other preclinical studies include:
- Microarray gene studies of primary and long-term cultured mesothelioma cells exposed to conventional chemotherapy drugs, hypomethylating agents, and tyrosine- kinase inhibitors
- Genetic profiles of mesenchymal tumors sensitive or resistant to gemcitabine, cisplatin, and bortezomib chemotherapy
- In collaboration with the Ludwig Institute for Cancer Research, discovery and definition of tumor-related peptide antigens detected in our patient material using Serex and related techniques, and the development of peptide and protein vaccines for immunotherapy.
Hospital News
Clinical Services
RELATED LINKS
- Radiation Oncology, NewYork-Presbyterian/Columbia
- Radiation Oncology, NewYork-Presbyterian/Weill Cornell
- General Thoracic Surgery, NewYork-Presbyterian/Columbia
- Herbert Irving Comprehensive Cancer Center
- Weill Cornell Division of Thoracic Surgery
- Weill Cornell Comprehensive Cancer Care and Blood Disorders
- Mesothelioma Connective Tissue Oncology Program, NewYork-Presbyterian/Columbia
